Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

TherapeuticsMD Q2 2026 Earnings: License Revenue and Net Income Decline

11 August 2026 · By · Wire by Fusion42

Published

11 August 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at tradingkey.com →

◆ Verified

Fusion42 · 12 August 2026 · Fusion42 review

TherapeuticsMD reported a 9.2% decline in Q2 2026 license revenue and a 69.9% drop in net income from continuing operations, driven by reduced sales of licensed products and uneven milestone payment timing. The company relies primarily on royalties from the Mayne License Agreement and faces risks from licensee sales performance and pending strategic alternatives.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Your biotech firm’s revenue could swing sharply quarter to quarter due to licencee sales and milestone timing. You must manage cash and strategic plans tightly while timing revenues from royalties and milestones carefully.

◆ Coverage

1 source · 11 Aug 2026

◆ Related on Wire

◆ Topics

Biotechroyalty-revenueearnings-declinepharma-licensingstrategic-alternativesmilestone-payments